Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation
- PMID: 16603729
- DOI: 10.1152/ajpgi.00521.2005
Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation
Abstract
Fatty liver disease (FLD), whether it is alcoholic FLD (AFLD) or nonalcoholic FLD (NAFLD), encompasses a morphological spectrum consisting of hepatic steatosis (fatty liver) and steatohepatitis. FLD has the inherent propensity to progress toward the development of cirrhosis and hepatocellular carcinoma. It is generally difficult to distinguish AFLD from NAFLD on morphological grounds alone despite the distinctions implied by these etiological designations. The indistinguishable spectrum of histological features of both AFLD and NAFLD suggests a possible convergence of pathogenetic mechanisms at some critical juncture that enables the progression of steatohepatitis toward cirrhosis and liver cancer. From a pathogenetic perspective, FLD may be considered a single disease with multiple etiologies. Excess energy consumption and reduced energy combustion appear to be critical events that culminate in lipid storage in the liver. Energy combustion in the liver is controlled by peroxisome proliferator-activated receptor (PPAR)-alpha-regulated mitochondrial and peroxisomal fatty acid beta-oxidation systems and the microsomal omega-oxidation system. PPAR-alpha, a receptor for peroxisome proliferators, functions as a sensor for fatty acids (lipid sensor), and ineffective PPAR-alpha sensing can lead to reduced energy burning resulting in hepatic steatosis and steatohepatitis. Delineation of the pathogenetic aspects of FLD is necessary for developing novel therapeutic strategies for this disease.
Similar articles
-
Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.J Gastroenterol Hepatol. 2004 Jul;19(7):799-804. doi: 10.1111/j.1440-1746.2004.03349.x. J Gastroenterol Hepatol. 2004. PMID: 15209628
-
PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.J Gastroenterol Hepatol. 2008 Jan;23(1):102-9. doi: 10.1111/j.1440-1746.2006.04819.x. J Gastroenterol Hepatol. 2008. PMID: 18171348
-
Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.Int J Mol Med. 2005 Oct;16(4):631-5. Int J Mol Med. 2005. PMID: 16142397
-
Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis.Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G194-8. doi: 10.1152/ajpgi.00413.2005. Am J Physiol Gastrointest Liver Physiol. 2006. PMID: 16407588 Review.
-
Adiponectin and alcoholic fatty liver disease.IUBMB Life. 2008 Dec;60(12):790-7. doi: 10.1002/iub.124. IUBMB Life. 2008. PMID: 18709650 Review.
Cited by
-
Dietary sanguinarine supplementation recovers the decrease in muscle quality and nutrient composition induced by high-fat diets of grass carp (Ctenopharyngodon idella).Anim Nutr. 2024 Apr 6;17:208-219. doi: 10.1016/j.aninu.2024.04.001. eCollection 2024 Jun. Anim Nutr. 2024. PMID: 38800733 Free PMC article.
-
Liquid Chromatography/Tandem Mass Spectrometry Analysis of Sophora flavescens Aiton and Protective Effects against Alcohol-Induced Liver Injury and Oxidative Stress in Mice.Antioxidants (Basel). 2024 Apr 28;13(5):541. doi: 10.3390/antiox13050541. Antioxidants (Basel). 2024. PMID: 38790646 Free PMC article.
-
Trans-omic analysis reveals opposite metabolic dysregulation between feeding and fasting in liver associated with obesity.iScience. 2024 Feb 26;27(3):109121. doi: 10.1016/j.isci.2024.109121. eCollection 2024 Mar 15. iScience. 2024. PMID: 38524370 Free PMC article.
-
Loss of flavin-containing monooxygenase 3 modulates dioxin-like polychlorinated biphenyl 126-induced oxidative stress and hepatotoxicity.Environ Res. 2024 Jun 1;250:118492. doi: 10.1016/j.envres.2024.118492. Epub 2024 Feb 17. Environ Res. 2024. PMID: 38373550
-
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).Metabolites. 2023 Dec 23;14(1):12. doi: 10.3390/metabo14010012. Metabolites. 2023. PMID: 38248815 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical